
Anne Nguyen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/746535/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy. Breast Cancer Research and Treatment, 2019, 176, 617-624.	2.5	7
2	A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial. Breast Cancer Research and Treatment, 2018, 171, 121-129.	2.5	17
3	Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Research and Treatment, 2012, 131, 907-914.	2.5	62
4	Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients. Journal of Clinical Pharmacology, 2010, 50, 450-458.	2.0	102
5	Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Research and Treatment, 2009, 115, 643-650.	2.5	37
6	Antiestrogen pathway (aromatase inhibitor). Pharmacogenetics and Genomics, 2009, 19, 554-555.	1.5	10
7	Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy. Menopause, 2009, 16, 653-659.	2.0	24
8	Estrogen Receptor Genotypes Influence Hot Flash Prevalence and Composite Score Before and After Tamoxifen Therapy. Journal of Clinical Oncology, 2008, 26, 5849-5854.	1.6	49
9	A Mixture Model Approach in Gene–Gene and Gene–Environmental Interactions for Binary Phenotypes. Journal of Biopharmaceutical Statistics, 2008, 18, 1150-1177.	0.8	6
10	Estimating a Positive False Discovery Rate for Variable Selection in Pharmacogenetic Studies. Journal of Biopharmaceutical Statistics, 2007, 17, 883-902.	0.8	2
11	The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Research and Treatment, 2007, 101, 113-121.	2.5	520
12	Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clinical Pharmacology and Therapeutics, 2006, 80, 61-74.	4.7	424
13	CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment. Journal of the National Cancer Institute, 2005, 97, 30-39.	6.3	867
14	Sequence diversity and functional characterization of the 5???-regulatory region of human CYP2C19. Pharmacogenetics and Genomics, 2003, 13, 199-206.	5.7	14